Sarepta's New CEO Bets on Biology: Q2 26 Shows Discipline but Guides Lower for 2026
Updated guidance, the rise of the siRNA platform, and a cash-generative base business frame a transition quarter for Sarepta.
SRPT · Earnings Call · 2026-08-05
A New Helmsman, a Tighter Course
When Michael Severino took the mic as Sarepta's new CEO, the market was listening for a reset. He delivered a clear one: the company narrowed its 2026 net product revenue guidance to $1.2–$1.3B, called the midpoint "the appropriate reference," and warned that second-half revenue would be "modestly lower" than the first half. The stock, already down 11% over the past 90 days, didn't find much relief. But inside the call was a much bigger story: a deliberate repositioning of Sarepta around its next-generation siRNA platform, with the commercial Duchenne franchise funding the transition.ELEVIDYS: Wait for Cohort 8
The commercial narrative remains anchored to cohort 8 data — the open-label study testing prophylactic sirolimus to prevent acute liver injury in non-ambulatory patients. As Louise Rodino-Klapac, president of R&D, reminded investors, “We expect to fully enroll the Endeavor Cohort 8 study by the end of 26... we now expect 12-week data from the full cohort in the first quarter of 27.” — Louise R. Rodino-Klapac, Senior Executive or Head of R&D · 2026-08-05 That timeline is a quarter later than the prior "year-end" expectation, reflecting sequential dosing by investigators rather than an enrollment problem. The hope is that a clean ALI signal will justify re-opening the non-ambulatory market and, per management, provide a path to restart the LGMD program on clinical hold. In the meantime, the PMO franchise (EXONDYS, AMONDYS, VVYONDYS) remains the bedrock: “PMO performance continues to reflect stable demand and sustained patient and physician confidence,” — Patrick Moss, Senior Executive or Head of Commercial · 2026-08-05 said commercial chief Patrick Moss. This emphasis on evidence isn't new; Moss told investors in May that “What is moving the needle is the efficacy data as well as the MRI data.” — Patrick Moss, Chief Commercial Officer · 2026-05-06 But the growth engine is clearly ELEVIDYS, and there the picture is choppier. Second-quarter net product revenue was $329M, with ELEVIDYS contributing $98M. While enrollment forms are improving quarter-over-quarter, the six-month lag to infusion means most of that uptick lands in 2027. Management was candid that third-quarter ELEVIDYS revenue will likely be down versus Q2. The company is asking investors to accept volatility in exchange for a long-term story.Biology First: The siRNA Pivot
The most enthusiastic segment of the call was reserved for the siRNA pipeline. Louise Rodino-Klapac framed the strategy bluntly: “Our strategy is built on a simple premise. Biology first.” — Louise R. Rodino-Klapac, Senior Executive or Head of R&D · 2026-08-05 She and Severino repeatedly flagged muscle concentration as the key differentiator, citing dose-dependent increases in skeletal muscle uptake for SRP-1001 (FSHD) and SRP-1003 (DM1) without dose-limiting toxicity. Interim MAD data are expected in the second half of 2026, and the company says these will include safety, PK, target knockdown, biomarker panels, and early functional assessments. "We are looking for the ability to dose escalate safely, so get to a dose that is appropriate for the phase 3 with very strong muscle concentration and significant knockdown," Rodino-Klapac told analysts. “quote” — Louise R. Rodino-Klapac, Senior Executive or Head of R&D · 2026-08-05 The focus on concentration has been building for a while; in February, she told investors that “we are looking for muscle concentration. And based on our preclinical data, we feel and the data from the SAD data so far that we can continue to dose escalate.” — Louise Rodino-Klapac, Chief Scientific Officer · 2026-02-25 The regulatory path is still open — accelerated or traditional approval will depend on data and the landscape, but management clearly believes the biology will drive either. Huntington's disease, the CNS program, is the wildcard. First proof-of-biology data are expected early next year, with CSF knockdown serving as a surrogate for blood-brain-barrier penetration. If successful, it would validate the transferrin-receptor delivery approach and de-risk the platform beyond muscle.Financial Discipline Backed by Cash
CFO Ryan Wong portrayed a company with a reset cost structure. Non-GAAP operating expenses for Q2 were $165M, down 44% year-over-year, and the company tightened full-year OpEx guidance to $800–$850M. “We delivered a strong financial performance in the second quarter... our ability to fund our most important commercial and R&D initiatives from a position of financial strength,” — Ryan H. Wong, Senior Executive or Chief Financial Officer (CFO) · 2026-08-05 said Wong. The balance sheet is notably healthier: $945M in cash and investments, up $197M sequentially, even after a $250M Arrowhead collaboration payment in Q1. The underlying base business generated roughly $240M of cash in H1, and recent debt refinancing reduces near-term maturities. The operating income series has oscillated wildly over the past decade, but the most recent quarter shows a clear pivot toward profitability, a message management repeated three times on the call. The guidance for total collaboration and other revenue was raised to $550–$600M on higher contract manufacturing from Roche. That mix shift — lower-margin manufacturing revenue offsetting product sales — explains why gross margin compresses even as cash grows.What Changes, What Doesn't
The near-term report card is mixed, but the strategic inflection is unambiguous. Sarepta is betting its future on a science-first narrative wrapped around benefit risk improvements and a cost-disciplined balance sheet. The market will need to see clean Cohort 8 data, strong MAD readouts, and a conversion of the elevated enrollment forms into 2027 revenue before it re-rates the stock. The new CEO's message: the Duchenne business is durable, the pipeline is differentiated, and the company can fund it independently. That's a coherent story — but the calendar of catalysts will decide whether it's a good one.We have 4 marketed products that make a real difference in patients' lives today. We have a compelling pipeline of siRNA therapeutics that will drive our future growth.